David Mathai
Psychiatrist and Assistant Professor at The Johns Hopkins University School of Medicine
Data updated
Research Footprint
David Mathai appears in 8 tracked papers (2020–2026), most studied alongside Psilocybin, Ketamine and MDMA, across Depressive Disorders, Adolescents and Anxiety Disorders.
Most-cited paper: The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review (89 citations).
Frequent co-authors: Albert Garcia-Romeu, Nathan Sepeda and Sandeep Nayak.
Background & Research
David Mathai is a psychiatrist and researcher affiliated with Johns Hopkins, where his work has focused on psychopharmacology, ketamine/esketamine, and psychedelic medicine. He has contributed to studies and reviews on psilocybin, dextromethorphan, dissociation, and psychedelic risk reduction, and has been described as serving in research and clinical roles at Johns Hopkins Bayview/Center for Psychedelic and Consciousness Research. He also appears to have ongoing clinical interests in integrated and psychedelic-informed psychiatric care.
Key Impact
He is a psychiatric researcher at Johns Hopkins whose work spans psilocybin, ketamine/esketamine, and psychedelic-assisted psychotherapy, with multiple publications on experiential and therapeutic outcomes.
Collaboration Network
21 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations David Mathai is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Baylor College of Medicine
Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.
View stakeholder →